A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-na?ve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

摘要

BackgroundThe standard-of-care regimen for chronic hepatitis C virus (HCV) infection in Korea, pegylated-interferon-alpha plus ribavirin, is poorly tolerated. Ledipasvir/sofosbuvir is a two-drug, fixed-dose combination tablet approved in the USA, European Union, and Japan for chronic genotype 1 HCV infection.MethodsThis single-arm, phase IIIb study (NCT02021656) investigated the efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination tablet for 12?weeks in treatment-na?ve and treatment-experienced Korean patients chronically infected with genotype 1 HCV with or without compensated cirrhosis.ResultsThe proportion of patients with sustained virologic response 12?weeks after treatment discontinuation (SVR12) was 99?% (92/93), with rates of 100?% (46/46) and 98?% (46/47) in treatment-na?ve and treatment-experienced patients, respectively. There were no on-treatment failures. One patient relapsed after the end of treatment. The most common treatment-emergent adverse events were headache (8?%, 7/93) and fatigue (6?%, 6/93). There were no grade 3 or 4 adverse events, seven grade 3 laboratory abnormalities, and one premature discontinuation of study treatment (due to nonserious mouth ulceration). None of the three reported serious adverse events were related to treatment.ConclusionsThese data suggest that 12?weeks of ledipasvir/sofosbuvir is effective and well tolerated in treatment-na?ve and treatment-experienced Korean patients with chronic genotype 1 HCV infection.